Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: A systematic review and meta-analysis

Journal of the American Heart Association

Volumn 6, Issue 5, 2017, Pages

  Baker, William L ^a   Buckley, Leo F ^b   Kelly, Michael S ^c   Bucheit, John D ^b   Parod, Eric D ^b   Brown, Roy ^b   Carbone, Salvatore ^b,d   Abbate, Antonio ^b   Dixon, Dave L ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c CHAPMAN UNIVERSITY   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Diabetes mellitus; Diabetic therapy glitazones; High blood pressure; Hypertension; Metformin; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 5-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1-HYDROXYMETHYL-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; FUSED HETEROCYCLIC RINGS; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CIRCADIAN RHYTHM; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ADULT; AGED; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS; DRUG EFFECTS; FEMALE; KIDNEY PROXIMAL TUBULE; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CANAGLIFLOZIN; CIRCADIAN RHYTHM; DIABETES MELLITUS; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85019390334     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.117.005686     Document Type: Review

References (36)

1. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2016;13:11-26.
2. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213-225.
3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedi JC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
4. U.S. Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517. htm. Accessed January 11, 2017.
5. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262-275.
6. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772.
7. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-161.
8. Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, Asayama K, Bjorklund-Bodegard K, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Filipovsky J, Imai Y, Wang J, Ibsen H, O'Brien E, Staessen JA; International Database onAmbulatory blood pressure in relation to Cardiovascular Outcomes Investigators. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension. 2013;61:964-971.
9. Schwartz JE, Burg MM, Shimbo D, Broderick JE, Stone AA, Ishikawa J, Sloan R, Yurgel T, Grossman S, Pickering TG. Clinic blood pressure underestimates ambulatory blood pressure in an untreated employer-based US population: results fromthe Masked Hypertension Study. Circulation. 2016;134:1794-1807.
10. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. DOI: 10.1186/2046-4053-4-1.
11. Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014. Chapters Available at: www.effectivehealthcare.a hrq.gov. Accessed April 12, 2017.
12. IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. DOI: 10.1186/1471-2288-14-25.
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
15. Townsend RR, Machin I, Ren J, Trujillo A, Kawaguchi M, Vijapurkar U, Damaraju CV, Pfeifer M. Reductions in mean 24-hour ambulatory blood pressure after 6-week Treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich). 2016;18:43-52.
16. Lambers-Heerspink HJ, De Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-862.
17. Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on reninangiotensin system blockade. Blood Press. 2016;25:93-103.
18. Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211-220.
19. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420-428.
20. Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure lowering effect of the sodium glucose co-transporter-2 inhibitor, ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805-808.
21. Cefalu WT, Leiter LA, Yoon K-H, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941-950.
22. Şkrtić M, Cherney DZI. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2015;24:96-103.
23. Wulffelé MG, Kooy A, Lehert P, Betst D, Donker AJM, Stehouwer CD. Does metformin decrease blood pressure in patients with type 2 diabetes intensively treated with insulin? Diabet Med. 2005;22:907-913.
24. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592-598.
25. Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, Braun D, Giaconia J, Malone J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6. DOI: 10.1186/1475-2840-9-6.
26. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38:132-139.
27. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731-737.
28. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol. 2008;7:10. DOI: 10.1186/1475-2840-7-10.
29. Tiwari S, Riazi S, Ecelbarger CA. Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol. 2007;293:974-984.
30. Heise T, Magnusson K, Heinemann L, Sawicki PT. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension. 1998;32:243-248.
31. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure. Circulation. 2003;108:2941-2948.
32. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Matthewus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375: 323-334.
33. Perseghin G, Solini A. The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovasc Diabetol. 2016;15:85. DOI: 10. 1186/s12933-016-0403-8.
34. Eguchi K, Pickering TG, Hoshide S, Ishikawa J, Schwartz JE, Shimada K, Kario K. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. Am J Hypertens. 2008;21:443-450.
35. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55-61.
36. Cherney DZ, Udell JA. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Greater Power Comes Great Responsibility. Circulation. 2016;134:1915-1917.